Latest Articles

On 24 September, European regulators cleared the way for GW Pharma’s cannabinoid medicinal product to treat patients with two rare, severe forms of epilepsy. The European Commission approved Epidyolex to treat seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome in patients aged two and over. The drug is the first to be approved using the centralized procedure, meaning that it is authorized to be placed on the market throughout the 28 Member States…